title: Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation.
abstract: OBJECTIVE
  To determine risk factors of umbilical cord blood transplantation (UCBT) for patients with lymphoid malignancies.
  
  
  METHODS
  We evaluated 104 adult patients (median age, 41 years) who underwent unrelated donor UCBT for lymphoid malignancies. UCB grafts were two-antigen human leukocyte antigen-mismatched in 68%, and were composed of one (n = 78) or two (n = 26) units. Diagnoses were non-Hodgkin's lymphoma (NHL, n = 61), Hodgkin's lymphoma (HL, n = 29), and chronic lymphocytic leukemia (CLL, n = 14), with 87% having advanced disease and 60% having experienced failure with a prior autologous transplant. Sixty-four percent of patients received a reduced-intensity conditioning regimen and 46% low-dose total-body irradiation (TBI). Median follow-up was 18 months.
  
  
  RESULTS
  Cumulative incidence of neutrophil engraftment was 84% by day 60, with greater engraftment in recipients of higher CD34(+) kg/cell dose (P = .0004). CI of non-relapse-related mortality (NRM) was 28% at 1 year, with a lower risk in patients treated with low-dose total-body irradiation (TBI; P = .03). Cumulative incidence of relapse or progression was 31% at 1 year, with a lower risk in recipients of double-unit UCBT (P = .03). The probability of progression-free survival (PFS) was 40% at 1 year, with improved survival in those with chemosensitive disease (49% v 34%; P = .03), who received conditioning regimens containing low-dose TBI (60% v 23%; P = .001), and higher nucleated cell dose (49% v 21%; P = .009).
  
  
  CONCLUSIONS
  UCBT is a viable treatment for adults with advanced lymphoid malignancies. Chemosensitive disease, use of low-dose TBI, and higher cell dose were factors associated with significantly better outcome.
authors.affiliation: Eurocord / ARTM-Hôpital Saint Louis, 1, Av Claude Vellefaux, 75475 Paris Cedex 10 France. celsoarrais@uol.com.br
authors.forename: Celso A
authors.initials: CA
authors.lastname: Rodrigues
authors.forename: Guillermo
authors.initials: G
authors.lastname: Sanz
authors.forename: Claudio G
authors.initials: CG
authors.lastname: Brunstein
authors.forename: Jaime
authors.initials: J
authors.lastname: Sanz
authors.forename: John E
authors.initials: JE
authors.lastname: Wagner
authors.forename: Marc
authors.initials: M
authors.lastname: Renaud
authors.forename: Marcos
authors.initials: M
authors.lastname: de Lima
authors.forename: Mitchell S
authors.initials: MS
authors.lastname: Cairo
authors.forename: Sabine
authors.initials: S
authors.lastname: Fürst
authors.forename: Bernard
authors.initials: B
authors.lastname: Rio
authors.forename: Christopher
authors.initials: C
authors.lastname: Dalley
authors.forename: Enric
authors.initials: E
authors.lastname: Carreras
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Harousseau
authors.forename: Mohamad
authors.initials: M
authors.lastname: Mohty
authors.forename: Denis
authors.initials: D
authors.lastname: Taveira
authors.forename: Peter
authors.initials: P
authors.lastname: Dreger
authors.forename: Anna
authors.initials: A
authors.lastname: Sureda
authors.forename: Eliane
authors.initials: E
authors.lastname: Gluckman
authors.forename: Vanderson
authors.initials: V
authors.lastname: Rocha
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D036101:Cord Blood Stem Cell Transplantation; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000628:therapy*; D008223:Lymphoma / Q000097:blood / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000166:cytology; D012307:Risk Factors; D019172:Transplantation Conditioning; D055815:Young Adult